FDA Grants Approval for Selexipag Application ANDA214055
The FDA has granted approval for the Selexipag application ANDA214055 submitted by RK Pharma.
Published: July 27, 2026
Updated: July 27, 2026
Author: Humanexa Intelligence
Therapeutic area: Pulmonology / PAH
Company: RK Pharma
Asset: Selexipag
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
RK Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of RK Pharma's Selexipag application is a significant development in the PAH market, enhancing RK Pharma's competitive position. This approval necessitates a reassessment of market strategies by competitors to maintain their market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry strategies and any subsequent competitive responses from other PAH therapies.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.